<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00419757</url>
  </required_header>
  <id_info>
    <org_study_id>D5896C00021</org_study_id>
    <nct_id>NCT00419757</nct_id>
  </id_info>
  <brief_title>An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma</brief_title>
  <official_title>A 12-week, Randomised, Double Blind, Active-controlled, Multi-centre, Phase IIIB Study Comparing the Efficacy and Safety of SYMBICORT® pMDI 160/4.5 mg x 2 Actuations Twice Daily Versus Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily, in Adult/Adolescent (&gt; 12 Yrs) Hispanic Subjects With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a
      medication approved by the Food and Drug Administration(FDA)) in the Hispanic population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morning Peak Expiratory Flow (AM PEF)</measure>
    <time_frame>Baseline (run-in) and throughout 12 weeks</time_frame>
    <description>Change from baseline (average of daily records over the 14 days of run-in) to the average of daily records over the treatment period of 12 weeks, with baseline value as covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pre-defined Asthma Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Asthma Events, defined as any of: decrease in lung function (FEV1 or AM PEF), use of rescue medication over maximum allowed per day, night awakening requiring use of rescue medication, exacerbation of asthma requiring medical assistance, use of not allowed asthma medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With &quot;Withdrawals Due to Pre-defined Asthma Events&quot;</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of participants with &quot;Withdrawals Due to Pre-defined Asthma Events&quot; as recorded in CRF. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Pre-dose Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline, 2, 6 and 12 weeks</time_frame>
    <description>Changes in pre-dose FEV1 from baseline to the average value over the treatment period, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in a Evening Peak Expiratory Flow (PM PEF)</measure>
    <time_frame>Baseline (run-in) and throughout 12 weeks</time_frame>
    <description>Change from baseline (average of daily records over the 14 days of run-in) to the average of daily records over the treatment period of 12 weeks with baseline as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nighttime Asthma Symptom Score From Baseline Through 12 Weeks</measure>
    <time_frame>Baseline (run-in) and throughout 12 weeks</time_frame>
    <description>Change from baseline in average of daily scores for nighttime asthma over 12 weeks of treatment, with baseline value as covariate.
Daily scale:
0 = No symptoms
1 = Mild symptoms
2 = Moderate symptoms
3 = Severe symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Daytime Asthma Symptom Score From Baseline Through 12 Weeks</measure>
    <time_frame>Baseline (run-in) and throughout 12 weeks</time_frame>
    <description>Change from baseline in average of daily scores for daytime asthma over 12 weeks of treatment, with baseline value as covariate.
Daily scale:
0 = No symptoms
1 = Mild symptoms
2 = Moderate symptoms
3 = Severe symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Asthma Related Awakenings Free Nights, From Baseline Through 12 Weeks</measure>
    <time_frame>Baseline (run-in) and throughout 12 weeks</time_frame>
    <description>Change from baseline in percentage of nights with awakenings due to asthma over 12 weeks of treatment, with baseline value as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rescue Medication Use Over 12 Weeks of Treatment</measure>
    <time_frame>Baseline (run-in) and throughout 12 weeks</time_frame>
    <description>Change from baseline in rescue medication use over 12 weeks of treatment with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rescue-free Days Over 12 Weeks of Treatment</measure>
    <time_frame>Baseline (run-in) and throughout 12 weeks</time_frame>
    <description>Change from baseline in percentage of rescue-free days over 12 weeks of treatment, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Symptom-free Days Over 12 Weeks of Treatment</measure>
    <time_frame>Baseline (run-in) and throughout 12 weeks</time_frame>
    <description>Change from baseline in percentage of symptom-free days over 12 weeks of treatment, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Global Assessment</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>The assessment was made using a 5-point Likert scale with 1=much better, 2=somewhat better, 3=comparable, 4=somewhat worse, and 5=much worse transformed to a binary variable with points 1 and 2 combined as &quot;Yes&quot; and points 3, 4, 5 as &quot;No&quot;. Percent of Participants that gave positive responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>The assessment was made using a 5-point scale with 1=much better, 2=somewhat better, 3=comparable, 4=somewhat worse, and 5=much worse transformed to a binary variable with points 1and 2 combined as &quot;Yes&quot; and points 3, 4, 5 as &quot;No&quot;. Percent of Participants that gave positive responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Control Relief Index</measure>
    <time_frame>Week 12</time_frame>
    <description>Mean scores (6-points scale, where 1-means the most positive opinion and 6-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0±100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Overall Perception of Medication</measure>
    <time_frame>Week 12</time_frame>
    <description>Mean scores (6 or 5-points scale, where 1-means the most positive opinion and 5/6-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0±100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Comparison With Other Medications</measure>
    <time_frame>Week 12</time_frame>
    <description>Mean scores (5-points scale, where 1-means the most positive opinion and 5-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0±100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">558</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Symbicort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>budesonide HFA pMDI 160 μg x 2 actuations twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/formoterol (SYMBICORT) pMDI</intervention_name>
    <description>SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily</description>
    <arm_group_label>Symbicort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide HFA pMDI</intervention_name>
    <description>Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily</description>
    <arm_group_label>Budesonide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female, Hispanic (self-reported), &gt; 12 years of age

          -  Moderate to severe asthma requiring treatment with an inhaled corticosteroid

          -  Diagnosis of asthma for at least 6 months

        Exclusion Criteria:

          -  Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral,
             ocular)

          -  Any significant disease or disorder that may jeopardize a subject's safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christer Hultquist, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naranja</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newburgh</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spring</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aguas Buenas</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caquas</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cidra</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Levittown</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ponce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>SanJuan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trujillo Alto</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2007</study_first_submitted>
  <study_first_submitted_qc>January 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2007</study_first_posted>
  <results_first_submitted>May 20, 2009</results_first_submitted>
  <results_first_submitted_qc>August 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 27, 2012</results_first_posted>
  <last_update_submitted>August 24, 2012</last_update_submitted>
  <last_update_submitted_qc>August 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate asthma</keyword>
  <keyword>Severe asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>39 centres in United States enrolled 558 patients with asthma into this study. 308 patients were excluded: 279 for incorrect enrollment/eligibility criteria not fulfilled, 14 for voluntary discontinuations, 2 for development of study specific discontinuation criteria, 2 for adverse events, 10 were lost to follow-up</recruitment_details>
      <pre_assignment_details>Male or female, Hispanic (self-reported), ≥12 years</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Symbicort</title>
          <description>SYMBICORT® pMDI 160/4.5 μg x 2actuations twice daily</description>
        </group>
        <group group_id="P2">
          <title>Budesonide</title>
          <description>Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127">Randomized patients</participants>
                <participants group_id="P2" count="123">Randomized patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109">Randomized patients</participants>
                <participants group_id="P2" count="102">Randomized patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study specific discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Multiple reasons</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Symbicort</title>
          <description>SYMBICORT® pMDI 160/4.5 μg x 2actuations twice daily</description>
        </group>
        <group group_id="B2">
          <title>Budesonide</title>
          <description>Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="127"/>
            <count group_id="B2" value="123"/>
            <count group_id="B3" value="250"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.6" spread="39.8"/>
                    <measurement group_id="B2" value="14.9" spread="37.0"/>
                    <measurement group_id="B3" value="15.6" spread="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Morning Peak Expiratory Flow (AM PEF)</title>
        <description>Change from baseline (average of daily records over the 14 days of run-in) to the average of daily records over the treatment period of 12 weeks, with baseline value as covariate.</description>
        <time_frame>Baseline (run-in) and throughout 12 weeks</time_frame>
        <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>SYMBICORT® pMDI 160/4.5 μg x 2actuations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Peak Expiratory Flow (AM PEF)</title>
          <description>Change from baseline (average of daily records over the 14 days of run-in) to the average of daily records over the treatment period of 12 weeks, with baseline value as covariate.</description>
          <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
          <units>Liters/minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.40" spread="6.0" lower_limit="+/-6.0"/>
                    <measurement group_id="O2" value="19.90" spread="6.5" lower_limit="+/-6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pre-defined Asthma Events</title>
        <description>Asthma Events, defined as any of: decrease in lung function (FEV1 or AM PEF), use of rescue medication over maximum allowed per day, night awakening requiring use of rescue medication, exacerbation of asthma requiring medical assistance, use of not allowed asthma medication</description>
        <time_frame>12 weeks</time_frame>
        <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>SYMBICORT® pMDI 160/4.5 μg x 2actuations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-defined Asthma Events</title>
          <description>Asthma Events, defined as any of: decrease in lung function (FEV1 or AM PEF), use of rescue medication over maximum allowed per day, night awakening requiring use of rescue medication, exacerbation of asthma requiring medical assistance, use of not allowed asthma medication</description>
          <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.20"/>
                    <measurement group_id="O2" value="31.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With &quot;Withdrawals Due to Pre-defined Asthma Events&quot;</title>
        <description>Percentage of participants with &quot;Withdrawals Due to Pre-defined Asthma Events&quot; as recorded in CRF. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
        <time_frame>12 weeks</time_frame>
        <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>SYMBICORT® pMDI 160/4.5 μg x 2actuations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With &quot;Withdrawals Due to Pre-defined Asthma Events&quot;</title>
          <description>Percentage of participants with &quot;Withdrawals Due to Pre-defined Asthma Events&quot; as recorded in CRF. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
          <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.10"/>
                    <measurement group_id="O2" value="6.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes Pre-dose Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Changes in pre-dose FEV1 from baseline to the average value over the treatment period, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
        <time_frame>Baseline, 2, 6 and 12 weeks</time_frame>
        <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>SYMBICORT® pMDI 160/4.5 μg x 2actuations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Pre-dose Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Changes in pre-dose FEV1 from baseline to the average value over the treatment period, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
          <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.03" lower_limit="+/-0.03"/>
                    <measurement group_id="O2" value="0.11" spread="0.03" lower_limit="+/-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in a Evening Peak Expiratory Flow (PM PEF)</title>
        <description>Change from baseline (average of daily records over the 14 days of run-in) to the average of daily records over the treatment period of 12 weeks with baseline as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
        <time_frame>Baseline (run-in) and throughout 12 weeks</time_frame>
        <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>SYMBICORT® pMDI 160/4.5 μg x 2actuations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in a Evening Peak Expiratory Flow (PM PEF)</title>
          <description>Change from baseline (average of daily records over the 14 days of run-in) to the average of daily records over the treatment period of 12 weeks with baseline as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
          <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
          <units>Liters/minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.60" spread="6.2" lower_limit="+/-6.2"/>
                    <measurement group_id="O2" value="15.80" spread="6.7" lower_limit="+/-6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Nighttime Asthma Symptom Score From Baseline Through 12 Weeks</title>
        <description>Change from baseline in average of daily scores for nighttime asthma over 12 weeks of treatment, with baseline value as covariate.
Daily scale:
0 = No symptoms
1 = Mild symptoms
2 = Moderate symptoms
3 = Severe symptoms</description>
        <time_frame>Baseline (run-in) and throughout 12 weeks</time_frame>
        <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>SYMBICORT® pMDI 160/4.5 μg x 2actuations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Nighttime Asthma Symptom Score From Baseline Through 12 Weeks</title>
          <description>Change from baseline in average of daily scores for nighttime asthma over 12 weeks of treatment, with baseline value as covariate.
Daily scale:
0 = No symptoms
1 = Mild symptoms
2 = Moderate symptoms
3 = Severe symptoms</description>
          <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.01" lower_limit="+/-0.01"/>
                    <measurement group_id="O2" value="-0.30" spread="0.01" lower_limit="+/-0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Daytime Asthma Symptom Score From Baseline Through 12 Weeks</title>
        <description>Change from baseline in average of daily scores for daytime asthma over 12 weeks of treatment, with baseline value as covariate.
Daily scale:
0 = No symptoms
1 = Mild symptoms
2 = Moderate symptoms
3 = Severe symptoms</description>
        <time_frame>Baseline (run-in) and throughout 12 weeks</time_frame>
        <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>SYMBICORT® pMDI 160/4.5 μg x 2actuations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Daytime Asthma Symptom Score From Baseline Through 12 Weeks</title>
          <description>Change from baseline in average of daily scores for daytime asthma over 12 weeks of treatment, with baseline value as covariate.
Daily scale:
0 = No symptoms
1 = Mild symptoms
2 = Moderate symptoms
3 = Severe symptoms</description>
          <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.01" lower_limit="+/-0.01"/>
                    <measurement group_id="O2" value="-0.30" spread="0.01" lower_limit="+/-0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Asthma Related Awakenings Free Nights, From Baseline Through 12 Weeks</title>
        <description>Change from baseline in percentage of nights with awakenings due to asthma over 12 weeks of treatment, with baseline value as covariate.</description>
        <time_frame>Baseline (run-in) and throughout 12 weeks</time_frame>
        <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>SYMBICORT® pMDI 160/4.5 μg x 2actuations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Asthma Related Awakenings Free Nights, From Baseline Through 12 Weeks</title>
          <description>Change from baseline in percentage of nights with awakenings due to asthma over 12 weeks of treatment, with baseline value as covariate.</description>
          <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
          <units>Percentage of nights</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.40" spread="1.7" lower_limit="+/-1.7"/>
                    <measurement group_id="O2" value="5.50" spread="1.9" lower_limit="+/-1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rescue Medication Use Over 12 Weeks of Treatment</title>
        <description>Change from baseline in rescue medication use over 12 weeks of treatment with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
        <time_frame>Baseline (run-in) and throughout 12 weeks</time_frame>
        <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>SYMBICORT® pMDI 160/4.5 μg x 2actuations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rescue Medication Use Over 12 Weeks of Treatment</title>
          <description>Change from baseline in rescue medication use over 12 weeks of treatment with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
          <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
          <units>puffs/day</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.20" lower_limit="+/-0.20"/>
                    <measurement group_id="O2" value="-0.60" spread="0.20" lower_limit="+/-0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rescue-free Days Over 12 Weeks of Treatment</title>
        <description>Change from baseline in percentage of rescue-free days over 12 weeks of treatment, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
        <time_frame>Baseline (run-in) and throughout 12 weeks</time_frame>
        <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>SYMBICORT® pMDI 160/4.5 μg x 2actuations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rescue-free Days Over 12 Weeks of Treatment</title>
          <description>Change from baseline in percentage of rescue-free days over 12 weeks of treatment, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
          <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
          <units>Percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.70" spread="3.30" lower_limit="+/-3.30"/>
                    <measurement group_id="O2" value="17.70" spread="3.50" lower_limit="+/-3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Symptom-free Days Over 12 Weeks of Treatment</title>
        <description>Change from baseline in percentage of symptom-free days over 12 weeks of treatment, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
        <time_frame>Baseline (run-in) and throughout 12 weeks</time_frame>
        <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>SYMBICORT® pMDI 160/4.5 μg x 2actuations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Symptom-free Days Over 12 Weeks of Treatment</title>
          <description>Change from baseline in percentage of symptom-free days over 12 weeks of treatment, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</description>
          <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
          <units>Percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.40" spread="3.30" lower_limit="+/-3.30"/>
                    <measurement group_id="O2" value="21.00" spread="3.50" lower_limit="+/-3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Global Assessment</title>
        <description>The assessment was made using a 5-point Likert scale with 1=much better, 2=somewhat better, 3=comparable, 4=somewhat worse, and 5=much worse transformed to a binary variable with points 1 and 2 combined as “Yes” and points 3, 4, 5 as &quot;No&quot;. Percent of Participants that gave positive responses.</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>SYMBICORT® pMDI 160/4.5 μg x 2actuations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Global Assessment</title>
          <description>The assessment was made using a 5-point Likert scale with 1=much better, 2=somewhat better, 3=comparable, 4=somewhat worse, and 5=much worse transformed to a binary variable with points 1 and 2 combined as “Yes” and points 3, 4, 5 as &quot;No&quot;. Percent of Participants that gave positive responses.</description>
          <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.70"/>
                    <measurement group_id="O2" value="86.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Assessment</title>
        <description>The assessment was made using a 5-point scale with 1=much better, 2=somewhat better, 3=comparable, 4=somewhat worse, and 5=much worse transformed to a binary variable with points 1and 2 combined as “Yes” and points 3, 4, 5 as &quot;No&quot;. Percent of Participants that gave positive responses.</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>SYMBICORT® pMDI 160/4.5 μg x 2actuations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Assessment</title>
          <description>The assessment was made using a 5-point scale with 1=much better, 2=somewhat better, 3=comparable, 4=somewhat worse, and 5=much worse transformed to a binary variable with points 1and 2 combined as “Yes” and points 3, 4, 5 as &quot;No&quot;. Percent of Participants that gave positive responses.</description>
          <population>Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
          <units>Perscentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.00"/>
                    <measurement group_id="O2" value="84.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Control Relief Index</title>
        <description>Mean scores (6-points scale, where 1-means the most positive opinion and 6-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0±100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.</description>
        <time_frame>Week 12</time_frame>
        <population>Only subjects 18 years and older, who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>SYMBICORT® pMDI 160/4.5 μg x 2actuations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Control Relief Index</title>
          <description>Mean scores (6-points scale, where 1-means the most positive opinion and 6-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0±100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.</description>
          <population>Only subjects 18 years and older, who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.20" spread="1.97" lower_limit="+/-1.97"/>
                    <measurement group_id="O2" value="82.50" spread="2.08" lower_limit="+/-2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Overall Perception of Medication</title>
        <description>Mean scores (6 or 5-points scale, where 1-means the most positive opinion and 5/6-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0±100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.</description>
        <time_frame>Week 12</time_frame>
        <population>Only subjects 18 years and older, who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>budesonide HFA pMDI 160 μg x 2 actuations twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Overall Perception of Medication</title>
          <description>Mean scores (6 or 5-points scale, where 1-means the most positive opinion and 5/6-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0±100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.</description>
          <population>Only subjects 18 years and older, who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.67" spread="1.79"/>
                    <measurement group_id="O2" value="86.66" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Comparison With Other Medications</title>
        <description>Mean scores (5-points scale, where 1-means the most positive opinion and 5-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0±100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.</description>
        <time_frame>Week 12</time_frame>
        <population>Only subjects 18 years and older, who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>budesonide HFA pMDI 160 μg x 2 actuations twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Comparison With Other Medications</title>
          <description>Mean scores (5-points scale, where 1-means the most positive opinion and 5-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0±100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.</description>
          <population>Only subjects 18 years and older, who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.45" spread="2.34"/>
                    <measurement group_id="O2" value="80.60" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Symbicort</title>
          <description>SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily</description>
        </group>
        <group group_id="E2">
          <title>Budesonide</title>
          <description>budesonide HFA pMDI 160 μg x 2 actuations twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Gastrointestinal Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Status Asthmaticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pharyngitis Streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

